Sandoz Holds Back On Cataract Drug Generic, Ending IP Suit
Sandoz Inc. has agreed to hold off on its generic version of Omeros Corp.'s cataract surgery drug Omidria until related patents expire in 15 years, putting an end to infringement litigation...To view the full article, register now.
Already a subscriber? Click here to view full article